Skip to main content

Table 2 Baseline characteristics of the treatment population (n = 31) at the time of study enrollment

From: A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

Baseline Characterisitcs of Treatment Population (n = 31)  
Median age (range) 65 (38–83)
Gender, n (%)
 Male 18 (58.1%)
 Female 13 (41.9%)
ECOG performance status
 0 11 (35.5%)
 1 20 (64.5%)
Primary site, n (%)
 Cutaneous 24 (77.4%)
 Unknown 5 (16.1%)
 Acral 2 (6.5%)
M substage, n (%)
 M1a 3 (9.7%)
 M1b 9 (29.0%)
 M1c 19 (61.3%)
LDH level, n (%)
 Normal 25 (80.6%)
 Elevated 6 (19.4%)
BRAF V600, n (%)
 wild type 26 (83.9%)
 V600E 3 (9.7%)
 V600K 2 (6.5%)
Prior systemic therapy, n (%)
 None 28 (90.3%)
 BRAF targeted therapy 1 (3.2%)
 cytotoxic chemotherapy 1 (3.2%)
 adjuvant vaccine clinical trial 1 (3.2%)